Bladder Cancer Data Update Lifts Shares ~20%; Piper Upgrades to Overweight
ENGN sits 58% above its 52-week low of $1.4 on elevated volume (7.3× avg).
Summary
enGene's updated Phase 2 LEGEND Cohort 1 data for detalimogene in high-risk, BCG-unresponsive non-muscle invasive bladder cancer showed improvement across all efficacy endpoints versus the April analysis, based on an October 29 data cut. The 8-K filed this morning reported 56% complete response at any time and 43% estimated. Piper Sandler's Allison Bratzel upgraded the stock to Overweight from Neutral with a $4 target, writing that the data "looks a lot better than the May update" and clears uncertainty over the BLA filing package. Shares climbed nearly 20% on the session. The company plans to start regulatory submissions this year and target a full BLA filing in H1 2027, with potential FDA approval next year.
At the time of this announcement, ENGN was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $148.1M. The 52-week trading range was $1.40 to $12.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.